Medical Condition News

RSS

Preoperative BB usage to help prevent POMI revealed at Vascular Annual Meeting

A regional quality improvement effort aimed at increasing the use of preoperative beta-blocker usage to help prevent postoperative myocardial infarction was revealed today at the 64th Vascular Annual Meeting presented by the Society for Vascular Surgery.

9 Jun 2010

$Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010$

Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010

Genmab A/S announced today that data from the pivotal trial of zalutumumab in refractory head and neck cancer patients will be presented today at the 2010 American Society of Clinical Oncology Annual Meeting, which will be held June 1-8 in Chicago, Illinois. This is the first controlled study to demonstrate that an EGFr-targeted antibody given as monotherapy induces a clinically meaningful improvement in progression free survival in patients with refractory head and neck cancer who have failed platinum-based chemotherapy.

9 Jun 2010

4% of South Asian people carry mutated gene that causes heart failure

One in 25 people from India and other south Asian countries carries a mutated gene that causes heart failure.

9 Jun 2010

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.

9 Jun 2010

VARI researchers identify enzyme that could help diagnose and treat cholangiocarcinoma

In collaboration with the National Cancer Centre, Singapore, Van Andel Research Institute researchers have identified an enzyme that could help diagnose and treat cholangiocarcinoma, a form of liver cancer that strikes up to 3,000 new patients each year in the United States.

9 Jun 2010

Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients

Clinical results from a Phase IIb study showed that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo (p<0.005) in improving overall sleep efficiency at night one and at the end of week four in patients with primary insomnia. MK-4305 was generally well-tolerated in the study. Orexins are neuropeptides (chemical messengers) that are released by specialized neurons in the hypothalamus region of the brain and are believed to be an important regulator of the brain's sleep-wake process.

9 Jun 2010

Short people at greater risk of developing CVD or CHD compared to tall people: Review

Short people are at greater risk of developing heart disease than tall people, according to the first systematic review and meta-analysis of all the available evidence, which is published online today (Wednesday 9 June) in the European Heart Journal.

9 Jun 2010

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced approval by the Norwegian Medicines Agency ('Statens Legemiddelverk') to test a combination of LTX-315 and GV1001 as vaccine therapy in patients with resected tumours. Lytix Biopharma CEO Gunnar Salid states, "We are delighted to announce the approval of our joint study to test a combination of two very interesting experimental drugs.

9 Jun 2010

Research findings hold promise for debilitating emotional symptoms of FXS

The study, which appears in the journal the Proceedings of the National Academy of Sciences, is also of potential therapeutic significance-it showed that a brief pharmacological treatment is capable of correcting some of these synaptic deficits in mice genetically engineered to model FXS.

9 Jun 2010

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

The Melanoma Network of Canada is excited with the new hope that long-anticipated results of a late-stage skin cancer trial brings to patients with advanced melanoma. The results, presented at the American Society of Clinical Oncology annual meeting, show increased survival with the experimental treatment ipilimumab in patients with previously-treated metastatic melanoma, the most deadly form of skin cancer.

9 Jun 2010

CPAP therapy effective at recouping memory abilities impaired by obstructive sleep apnea

Continuous positive airway pressure therapy helps restore memory consolidation in adults with obstructive sleep apnea, suggests a research abstract that will be presented Wednesday, June 9, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

9 Jun 2010

Insulin delivery devices help diabetic patients optimize blood glucose control, minimize chronic health problems

The growing use of insulin delivery devices such as pens and pumps may help individuals with diabetes optimize blood glucose control and minimize their risk for chronic health problems associated with diabetes, as described in a Special Supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc.

9 Jun 2010

Switching to healthier diet can slow or reverse cognitive impairment in patients with Alzheimer's Disease: Study

Patients in the early to moderate stages of Alzheimer's Disease could have their cognitive impairment slowed or even reversed by switching to a healthier diet, according to researchers at Temple University.

9 Jun 2010

PharmaMar commences Aplidin Phase III registration trial for multiple myeloma

PharmaMar SA today announced that a registration trial in relapsed/refractory multiple myeloma patients has been initiated with Aplidin(R) (plitidepsin) in combination with dexamethasone versus dexamethasone alone.

9 Jun 2010

Lubiprostone phase 3 clinical trial in Japan for chronic idiopathic constipation meets primary endpoint

Sucampo Pharmaceuticals, Inc. and Abbott today announced that a pivotal phase 3 clinical trial of lubiprostone for chronic idiopathic constipation (CIC) in Japanese patients met its primary endpoint with statistical significance and demonstrated a safety profile consistent with previously reported clinical lubiprostone data.

9 Jun 2010

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

TransTech Pharma, Inc and Forest Laboratories, Inc., today announced that TransTech Pharma and Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. have entered into a license agreement for the development and commercialization of small molecule compounds discovered and developed by TransTech Pharma.

9 Jun 2010

Researchers look at exercise as new way to slow degenerative processes of ALS

University of Alberta researchers are looking at exercise as a new way to slow the degenerative processes of ALS, commonly known as Lou Gehrig's disease. Dr. Kelvin Jones, a recipient of this year's ALS Canada Discovery Grant, has been pioneering research in this field for four years, using mice genetically altered to present familial ALS. He's found that exercise has a positive impact on the mice, slowing the disease significantly.

9 Jun 2010

CPRIT presents a $300,000 check to UNT Health Science Center for cancer research

The Cancer Prevention and Research Institute of Texas recently presented a $300,000 check to the University of North Texas Health Science Center. The check was accepted by the UNT Health Science Center Provost Thomas Yorio, Ph.D., and Richard Kurz, Ph.D., dean of the School of Public Health.

9 Jun 2010

Biogen, Elan launch My MS Health, a web-based PRO research program

Biogen Idec and Elan Corporation, plc, in collaboration with EPI-Q, Inc. and Avatar International, LLC, today announced the launch of My MS Health, a first-of-its-kind, web-based, patient-reported outcomes research program. My MS Health is designed to track and provide instant reports on patient function and quality of life using validated measures over time.

9 Jun 2010

USTPO awards Melior Discovery Notice of Allowance for type II diabetes and obesity drug candidate

Melior Discovery, Inc. announced today the United States Patent and Trademark Office (USTPO) has awarded a Notice of Allowance for a broad patent application covering the Company's use of MLR-1023 for, among other things, the treatment of type II diabetes and obesity. The patent will cover use of MLR-1023 for the treatment of type II diabetes, obesity and metabolic syndrome, including its use in combination with other compounds and as a component in other drugs.

8 Jun 2010

Medical Condition News

Preoperative BB usage to help prevent POMI revealed at Vascular Annual Meeting

Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010

4% of South Asian people carry mutated gene that causes heart failure

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

VARI researchers identify enzyme that could help diagnose and treat cholangiocarcinoma

Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients

Short people at greater risk of developing CVD or CHD compared to tall people: Review

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

Research findings hold promise for debilitating emotional symptoms of FXS

Experimental drug ipilimumab increases overall survival in patients with metastatic melanoma: Study

CPAP therapy effective at recouping memory abilities impaired by obstructive sleep apnea

Insulin delivery devices help diabetic patients optimize blood glucose control, minimize chronic health problems

Switching to healthier diet can slow or reverse cognitive impairment in patients with Alzheimer's Disease: Study

PharmaMar commences Aplidin Phase III registration trial for multiple myeloma

Lubiprostone phase 3 clinical trial in Japan for chronic idiopathic constipation meets primary endpoint

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

Researchers look at exercise as new way to slow degenerative processes of ALS

CPRIT presents a $300,000 check to UNT Health Science Center for cancer research

Biogen, Elan launch My MS Health, a web-based PRO research program

USTPO awards Melior Discovery Notice of Allowance for type II diabetes and obesity drug candidate

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News